Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Daratumumab
Related studies linked through entity extraction aliases.
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE2
Daratumumab Plus Ibrutinib in Patients With WaldenstrÓ§m's Macroglobulinemia
- Status
- TERMINATED
- Phase
- PHASE2
Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE2
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
- Status
- TERMINATED
- Phase
- PHASE2
An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE1
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Short Course Daratumumab in Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE2